These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23643457)

  • 1. Implications of early treatment among Medicaid patients with Alzheimer's disease.
    Geldmacher DS; Kirson NY; Birnbaum HG; Eapen S; Kantor E; Cummings AK; Joish VN
    Alzheimers Dement; 2014 Mar; 10(2):214-24. PubMed ID: 23643457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-diagnosis excess acute care costs in Alzheimer's patients among a US Medicaid population.
    Geldmacher DS; Kirson NY; Birnbaum HG; Eapen S; Kantor E; Cummings AK; Joish VN
    Appl Health Econ Health Policy; 2013 Aug; 11(4):407-13. PubMed ID: 23700254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender Differences: A Lifetime Analysis of the Economic Burden of Alzheimer's Disease.
    Yang Z; Levey A
    Womens Health Issues; 2015; 25(5):436-40. PubMed ID: 26363924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between severity of Alzheimer's disease and costs of caring.
    Hux MJ; O'Brien BJ; Iskedjian M; Goeree R; Gagnon M; Gauthier S
    CMAJ; 1998 Sep; 159(5):457-65. PubMed ID: 9757169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost of Alzheimer's disease in managed care: a cross-sectional study.
    Leon J; Neumann PJ
    Am J Manag Care; 1999 Jul; 5(7):867-77. PubMed ID: 10557408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2012 Alzheimer's disease facts and figures.
    Alzheimer's Association
    Alzheimers Dement; 2012; 8(2):131-68. PubMed ID: 22404854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early identification and treatment of Alzheimer's disease: social and fiscal outcomes.
    Weimer DL; Sager MA
    Alzheimers Dement; 2009 May; 5(3):215-26. PubMed ID: 19362885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Potential Impact of Alzheimer's Disease Early Treatment on Societal Costs of Care in Czechia: A Simulation Approach.
    Broulikova HM; Sladek V; Arltova M; Cerny J
    J Ment Health Policy Econ; 2018 Dec; 21(4):147-161. PubMed ID: 30676992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The estimated costs and savings of medical nutrition therapy: the Medicare population.
    Sheils JF; Rubin R; Stapleton DC
    J Am Diet Assoc; 1999 Apr; 99(4):428-35. PubMed ID: 10207394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical costs of Alzheimer's disease misdiagnosis among US Medicare beneficiaries.
    Hunter CA; Kirson NY; Desai U; Cummings AK; Faries DE; Birnbaum HG
    Alzheimers Dement; 2015 Aug; 11(8):887-95. PubMed ID: 26206626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study.
    Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J
    J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.
    Rice DP; Fillit HM; Max W; Knopman DS; Lloyd JR; Duttagupta S
    Am J Manag Care; 2001 Aug; 7(8):809-18. PubMed ID: 11519239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictors of long-term institutionalization in patients with Alzheimer's disease: role of caregiver burden].
    Hirono N; Tsukamoto N; Inoue M; Moriwaki Y; Mori E
    No To Shinkei; 2002 Sep; 54(9):812-8. PubMed ID: 12428367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.
    Black CM; Fillit H; Xie L; Hu X; Kariburyo MF; Ambegaonkar BM; Baser O; Yuce H; Khandker RK
    J Alzheimers Dis; 2018; 61(1):185-193. PubMed ID: 29103033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.
    Garfield FB; Getsios D; Caro JJ; Wimo A; Winblad B
    Pharmacoeconomics; 2002; 20(9):629-37. PubMed ID: 12141890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy.
    Fillit H; Hill JW; Futterman R
    Fam Med; 2002; 34(7):528-35. PubMed ID: 12144008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings.
    Reese JP; Hessmann P; Seeberg G; Henkel D; Hirzmann P; Rieke J; Baum E; Dannhoff F; Müller MJ; Jessen F; Geldsetzer MB; Dodel R
    J Alzheimers Dis; 2011; 27(4):723-36. PubMed ID: 21876256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2016 Alzheimer's disease facts and figures.
    Alzheimer's Association
    Alzheimers Dement; 2016 Apr; 12(4):459-509. PubMed ID: 27570871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Snyder EH; Bala MV; Richter A; Mauskopf JA
    Pharmacoeconomics; 2000 Apr; 17(4):351-60. PubMed ID: 10947490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.